{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:28:15Z","timestamp":1786606095010,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,12]]},"DOI":"10.7759\/cureus.114451","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:41:48Z","timestamp":1786603308000},"source":"Crossref","is-referenced-by-count":0,"title":["Colchicine and Major Adverse Cardiovascular Events in Patients With Established Coronary or Cerebrovascular Atherosclerotic Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.7759","author":[{"given":"Ahmed Alameleman","family":"Edris Ebrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaza Bakri","family":"Osman Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Omera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Hassan","family":"Sidahmed Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areij Awad","family":"Osman Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia Salih","family":"Mohammed Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nibras Elfatih Hussein","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra Eltahir","family":"Mohamed Gamareldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae557","article-title":"Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease","volume":"45","author":"Mazhar F","year":"2024","unstructured":"Mazhar F, Faucon AL, Fu EL, et al.. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease. Eur Heart J. 2024, 45:4719-30. 10.1093\/eurheartj\/ehae557","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson GK","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352:1685-95. 10.1056\/NEJMra043430","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker PM","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al.. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017, 377:1119-31. 10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation","volume":"269","author":"Mart\u00ednez GJ","year":"2018","unstructured":"Mart\u00ednez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018, 269:262-71. 10.1016\/j.atherosclerosis.2017.12.027","journal-title":"Atherosclerosis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon F","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006, 440:237-41. 10.1038\/nature04516","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab221","article-title":"Colchicine and the heart","volume":"42","author":"Imazio M","year":"2021","unstructured":"Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021, 42:2745-60. 10.1093\/eurheartj\/ehab221","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf SM","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013, 61:404-10. 10.1016\/j.jacc.2012.10.027","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif JC","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, et al.. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019, 381:2497-505. 10.1056\/NEJMoa1912388","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf SM","year":"2020","unstructured":"Nidorf SM, Fiolet AT, Mosterd A, et al.. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020, 383:1838-47. 10.1056\/NEJMoa2021372","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren FL","year":"2021","unstructured":"Visseren FL, Mach F, Smulders YM, et al.. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021, 42:3227-337. 10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001168","article-title":"AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani SS","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, et al.. AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023, 148:e9-e119. 10.1161\/CIR.0000000000001168","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints C","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al.. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024, 45:3415-537. 10.1093\/eurheartj\/ehae177","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet AT","year":"2021","unstructured":"Fiolet AT, Opstal TS, Mosterd A, et al.. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021, 42:2765-75. 10.1093\/eurheartj\/ehab115","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00968-1","article-title":"Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial","volume":"404","author":"Kelly P","year":"2024","unstructured":"Kelly P, Lemmens R, Weimar C, et al.. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. Lancet. 2024, 404:125-33. 10.1016\/S0140-6736(24)00968-1","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-079061","article-title":"Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial","volume":"385","author":"Li J","year":"2024","unstructured":"Li J, Meng X, Shi FD, et al.. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024, 385:e079061. 10.1136\/bmj-2023-079061","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly SS","year":"2025","unstructured":"Jolly SS, d'Entremont MA, Lee SF, et al.. Colchicine in acute myocardial infarction. N Engl J Med. 2025, 392:633-42. 10.1056\/NEJMoa2405922","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014808.pub2","article-title":"Colchicine for the secondary prevention of cardiovascular events","volume":"11","author":"Ebrahimi F","year":"2025","unstructured":"Ebrahimi F, Ebrahimi R, Beer M, et al.. Colchicine for the secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2025, 11:CD014808. 10.1002\/14651858.CD014808.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf174","article-title":"Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis","volume":"46","author":"Samuel M","year":"2025","unstructured":"Samuel M, Berry C, Dub\u00e9 MP, et al.. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J. 2025, 46:2552-63. 10.1093\/eurheartj\/ehaf174","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf210","article-title":"Colchicine for secondary prevention of vascular events: a meta-analysis of trials","volume":"46","author":"d'Entremont MA","year":"2025","unstructured":"d'Entremont MA, Poorthuis MH, Fiolet AT, et al.. Colchicine for secondary prevention of vascular events: a meta-analysis of trials. Eur Heart J. 2025, 46:2564-75. 10.1093\/eurheartj\/ehaf210","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986, 7:177-88. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout J","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014, 14:25. 10.1186\/1471-2288-14-25","journal-title":"BMC Med Res Methodol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins JP","year":"2009","unstructured":"Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009, 172:137-59. 10.1111\/j.1467-985X.2008.00552.x","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong DC","year":"2020","unstructured":"Tong DC, Quinn S, Nasis A, et al.. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020, 142:1890-900. 10.1161\/CIRCULATIONAHA.120.050771","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-02393-9","article-title":"Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial","volume":"21","author":"Akrami M","year":"2021","unstructured":"Akrami M, Izadpanah P, Bazrafshan M, Hatamipour U, Nouraein N, Drissi HB, Manafi A. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc Disord. 2021, 21:583. 10.1186\/s12872-021-02393-9","journal-title":"BMC Cardiovasc Disord"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.70238","article-title":"Efficacy and safety of colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis","volume":"106","author":"Ahmed M","year":"2025","unstructured":"Ahmed M, Fahim MA, Humayun M, Sajid B, Ahmad S, Asghar MS. Efficacy and safety of colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2025, 106:3675-89. 10.1002\/ccd.70238","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2046","article-title":"Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials","volume":"295","author":"Briel M","year":"2006","unstructured":"Briel M, Schwartz GG, Thompson PL, et al.. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006, 295:2046-56. 10.1001\/jama.295.17.2046","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-025-00743-y","article-title":"Colchicine for the secondary prevention of cardiovascular diseases: a cumulative-dose meta-analysis of randomized controlled trials including 31,397 subjects worldwide","volume":"26","author":"Li HY","year":"2026","unstructured":"Li HY, Cheriyan J, Chan TK, Yiu KH, Tse HF, Wilkinson IB, Chan YH. Colchicine for the secondary prevention of cardiovascular diseases: a cumulative-dose meta-analysis of randomized controlled trials including 31,397 subjects worldwide. Am J Cardiovasc Drugs. 2026, 26:107-20. 10.1007\/s40256-025-00743-y","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6802","article-title":"Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study","volume":"368","author":"Moustgaard H","year":"2020","unstructured":"Moustgaard H, Clayton GL, Jones HE, et al.. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. BMJ. 2020, 368:l6802. 10.1136\/bmj.l6802","journal-title":"BMJ"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres A","year":"2013","unstructured":"Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ. 2013, 346:f2304. 10.1136\/bmj.f2304","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf266","article-title":"Colchicine in secondary prevention: making sense out of diversity","volume":"46","author":"Pocock SJ","year":"2025","unstructured":"Pocock SJ, Mendieta G. Colchicine in secondary prevention: making sense out of diversity. Eur Heart J. 2025, 46:2576-8. 10.1093\/eurheartj\/ehaf266","journal-title":"Eur Heart J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae546","article-title":"Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis","volume":"45","author":"Zuriaga MA","year":"2024","unstructured":"Zuriaga MA, Yu Z, Matesanz N, et al.. Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. Eur Heart J. 2024, 45:4601-15. 10.1093\/eurheartj\/ehae546","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaf011","article-title":"CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction","volume":"11","author":"Laudani C","year":"2025","unstructured":"Laudani C, Abbate A, Angiolillo DJ, Galli M. CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2025, 11:215-7. 10.1093\/ehjcvp\/pvaf011","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week","volume":"82","author":"Nelson K","year":"2023","unstructured":"Nelson K, Fuster V, Ridker PM. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2023, 82:648-60. 10.1016\/j.jacc.2023.05.055","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521379-colchicine-and-major-adverse-cardiovascular-events-in-patients-with-established-coronary-or-cerebrovascular-atherosclerotic-disease-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:41:49Z","timestamp":1786603309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521379-colchicine-and-major-adverse-cardiovascular-events-in-patients-with-established-coronary-or-cerebrovascular-atherosclerotic-disease-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.114451","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}